MIMEDX GROUP, INC.MDXGEarnings & Financial Report
MiMedx is an American biomedical company based in Marietta, Georgia, founded in 2008. Using tissues from birth such as the placenta, amniotic sac, and umbilical cord, MiMedx creates skin for skin grafts for medical use.
MDXG Q4 2025 Key Financial Metrics
营收
$118.1M
毛利润
$99.0M
营业利润
$21.1M
净利润
$15.2M
毛利率
83.9%
营业利润率
17.8%
净利率
12.9%
同比增长
27.1%
EPS
$0.10
资金流向
MIMEDX GROUP, INC. Q4 2025 Financial Summary
MIMEDX GROUP, INC. reported revenue of $118.1M (up 27.1% YoY) for Q4 2025, with a net profit of $15.2M (up 104.2% YoY) (12.9% margin). Cost of goods sold was $19.1M, operating expenses totaled $78.0M.
Key Financial Metrics
| Total Revenue | $118.1M |
|---|---|
| Net Profit | $15.2M |
| Gross Margin | 83.9% |
| Operating Margin | 17.8% |
| Report Period | Q4 2025 |
Revenue Breakdown
MIMEDX GROUP, INC. Q4 2025 revenue of $118.1M breaks down across 2 segments, led by Wound at $78.7M (66.6% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Wound | $78.7M | 66.6% |
| Surgical | $39.4M | 33.4% |
MIMEDX GROUP, INC. Revenue by Segment — Quarterly Trend
MIMEDX GROUP, INC. revenue by segment across the last 4 reported quarters, showing how each business line (such as Wound and Surgical) has evolved quarter over quarter.
| Segment | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Wound | $78.7M | $77.1M | $64.5M | $56.1M |
| Surgical | $39.4M | $36.6M | $34.1M | $32.1M |
MIMEDX GROUP, INC. Annual Revenue by Year
MIMEDX GROUP, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $418.6M). Click any linked year to see what changed vs the prior 10-K.
MIMEDX GROUP, INC. Quarterly Revenue & Net Profit History
MIMEDX GROUP, INC. quarterly results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 2025 | $118.1M | +27.1% | $15.2M | 12.9% |
| Q3 2025 | $113.7M | +35.3% | $16.7M | 14.7% |
| Q2 2025 | $98.6M | +13.1% | $9.6M | 9.8% |
| Q1 2025 | $88.2M | +4.1% | $7.0M | 8.0% |
| Q4 2024 | $92.9M | +7.0% | $7.4M | 8.0% |
| Q3 2024 | $84.1M | +2.9% | $8.1M | 9.6% |
| Q2 2024 | $87.2M | +7.3% | $17.6M | 20.2% |
| Q1 2024 | $84.7M | +18.2% | $9.3M | 10.9% |
利润表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 营收 | $84.7M | $87.2M | $84.1M | $92.9M | $88.2M | $98.6M | $113.7M | $118.1M |
| 同比增长 | 18.2% | 7.3% | 2.9% | 7.0% | 4.1% | 13.1% | 35.3% | 27.1% |
资产负债表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 总资产 | $221.7M | $230.2M | $243.9M | $263.9M | $270.4M | $291.1M | $319.0M | $342.7M |
| 总负债 | $66.0M | $62.1M | $62.9M | $70.8M | $67.6M | $74.5M | $80.0M | $86.1M |
| 股东权益 | $155.7M | $168.0M | $181.0M | $193.1M | $202.8M | $216.6M | $238.9M | $256.5M |
现金流量表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 经营性现金流 | $6.0M | $21.8M | $19.6M | $18.8M | $5.3M | $14.4M | $29.3M | $25.0M |